Excellent article Joe. ADAPT is King and the Admedus TAVR device will be a game changer due to the durability of the valve..... Not only will this device be so much cheaper to produce due to the valve and needing 10x less sutures, and not only will surgeons save much valuable time due to the device coming pre-packaged and sterilized but most importantly, for the patient...... the valve will last and not deteriorate structurally.
I am expecting a deal in <6 months.
Why our TAVR will win, page-2
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$9.99 |
Change
-0.910(8.35%) |
Mkt cap ! $211.1M | |||
| Open | High | Low | Value | Volume |
| $10.50 | $10.79 | $9.30 | $1.477M | 149.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2000 | $9.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $9.99 | 1999 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| AVR (ASX) Chart |